Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns?
- 1 August 2004
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 10 (20) , 2463-2475
Abstract
The cardiovascular toxicity of older generation of tricyclic antidepressants (e.g. imipramine, desipramine, amitriptyline, clomipramine) and neuroleptics (e.g. haloperidol, droperidol, thioridazine, pimozide) is well established. These drugs inhibit cardiovascular Na+, Ca2+ and K+ channels often leading to life-threatening arrhythmia. To overcome the toxicity of old generation of antidepressants and antipsychotics, selective serotonin reuptake inhibitor antidepressants (SSRIs: fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, venlafaxin) and several new antipsychotics (e.g. clozapine, olanzapine, risperidone, sertindole, aripiprazole, ziprasidone, quetiapine) were introduced during the past decade. Although these new compounds are not more effective in treating psychiatric disorders than older medications, they gained incredible popularity since they have been reported to have fewer and more benign side effect profile (including cardiovascular) than predecessors. Surprisingly, an increasing number of case reports have demonstrated that the use of SSRIs and new antipsychotics (e.g. clozapine, olanzapine, risperidone, sertindole, aripiprazole, ziprasidone, quetiapine) is associated with cases of arrhythmias, prolonged QTc interval on electrocardiogram (ECG) and orthostatic hypotension in patients lacking cardiovascular disorders, raising new concerns about the putative cardiovascular safety of these compounds. In agreement with these clinical reports these new compounds indeed show marked cardiovascular depressant effects in different mammalian and human cardiovascular preparations by inhibiting cardiac and vascular Na+, Ca2+ and K+ channels. Taken together, these results suggest that the new generation of antidepressants and antipsychotics also have clinically important cardiac as well as vascular effects. Clinicians should be more vigilant about these potential adverse reactions and ECG control may be suggested during therapy, especially in patients with cardiovascular disorders. The primary goal of this review is to shed light on the recently observed clinically important cardiovascular effects of new antidepressants and antipsychotics and discuss the mechanism beyond this phenomenon.Keywords
This publication has 98 references indexed in Scilit:
- Effect of fluoxetine on a neuronal, voltage‐dependent potassium channel (Kv1.1)British Journal of Pharmacology, 1997
- Tachycardia, Orthostatic Hypotension and Profound Weakness Due to Concomitant Use of Fluoxetine and NifedipinePharmacopsychiatry, 1997
- Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publicationLife Sciences, 1995
- Mixed fluoxetine/loxapine overdose and atrial flutterAnnals of Emergency Medicine, 1994
- Fluoxetine-induced inhibition of synaptosomal [3H] 5-HT release: Possible CA2+-channel inhibitionLife Sciences, 1992
- Drug-induced supraventricular tachycardia: A case report of fluoxetineAnnals of Emergency Medicine, 1991
- Epidemiology of fatal tricyclic antidepressant ingestion: implications for managementAnnals of Emergency Medicine, 1985
- The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations.Circulation, 1979
- Antihypertensive effects of fluoxetine and L-5-hydroxytryptophan in ratsLife Sciences, 1979
- Cardiac Antiarrhythmic Effect of Imipramine HydrochlorideNew England Journal of Medicine, 1977